Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.61 |
| ▸ | HTR3B | O95264 | 5/20 | 0.61 |
| ▸ | HTR3A | P46098 | 5/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4897454 | 0.98 | ADRB1 (0.69) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5231016 | 0.94 | ADRB1 (0.63) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30609657 | 0.86 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1186845 | 0.86 | ADRB1 (0.71) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1779990 | 0.85 | CYP2D6 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL23843625 | 0.83 | ABCG2 (0.48) | ADRB1ALDH1A1 | |
| SCHEMBL232689 | 0.83 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL478208 | 0.83 | ADRB1 (0.57) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL8318106 | 0.81 | ADRB1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL2959681 | 0.81 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-02-24 | — | — | US | disclosed |
| CN-112437768-B | Novel functionalized lactams as modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-112239433-B | Cyclohexane derivative, preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20220306629-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2022-09-29 | — | — | US | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| EP-1189903-B1 | NOVEL BENZO[F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-28 | — | — | EP | disclosed |
| US-6566362-B2 | Use as topical antibiotics | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2002-09-26 | — | — | US | disclosed |
| EP-1189903-A1 | NOVEL BENZO F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001002396-A1 | NOVEL BENZO[F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2001-01-11 | — | — | WO | disclosed |
| US-4575555-A | ANTIDEPRESSANTS | MEAD JOHNSON & COMPANY (US) | 1986-03-11 | — | — | US | disclosed |
| US-4552878-A | ANTIDEPRESSANTS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1985-11-12 | — | — | US | disclosed |
| US-4487773-A | ANTISEROTONINE AGENTS | MEAD JOHNSON & COMPANY (US) | 1984-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR1B, HTR7, HTR6 | ADRB1 63/4885HTR3E 27/4885HTR3B 6/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | ADRB1 371/4885HTR3E 1510/4885HTR3B 1000/4885 |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR5A | ADRB1 89/4885HTR3E 19/4885HTR3B 17/4885 |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | ADRB1 3478/4885HTR3E 1217/4885HTR3B 1812/4885 |
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, TPH2 | ADRB1 111/4885HTR3E 21/4885HTR3B 13/4885 |
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | KCNQ2, KCNQ1, KCNQ4 | ADRB1 469/4885HTR3E 2221/4885HTR3B 948/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | ADRB1 3478/4885HTR3E 1217/4885HTR3B 1812/4885 |
| US-20220306629-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR1A | ADRB1 98/4885HTR3E 18/4885HTR3B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.